The U.S. Biomedical Advanced Research and Development Authority (BARDA) announced two awards Wednesday for “advanced development” of investigational drugs targeting antibiotic-resistant infections.

Massachusetts-based Vedanta Biosciences scored up to $76.9 million ($7.4 million upfront) to complete an ongoing Phase 2 trial and continue clinical development of VE303—a novel, human microbiome-derived treatment for high-risk C. difficile infection. The drug becomes the second CARB-X-…

CARB-X announced last week that it is awarding Vedanta Biosciences up to $5.8 million upfront and up to $3.5 million in potential milestone payments to develop a new category of oral antibiotics designed to help combat multi-drug-resistant bacteria by restoring healthy microbiota in people at high risk of developing infections.

In 2017, CARB-X also awarded the Massachusetts-based company $5.4 million to support its recurrent C. difficile infection treatment.